3 results
Primary Part 1:-To evaluate ORR in participants treated with MK-4280A plus EV (Arm A), MK-7684A plus EV (Arm B), and pembrolizumab plus EV(Arm C) per RECIST 1.1 by BICR.- To evaluate the safety and tolerability in participants treated with MK-4280A…
The aim of the trial is to individualize treatment for each patient by adapting it to early response and to treat only those patients with addiotional radiotherapy who show an inadequate treatment response. The degree of treatment response is…
To assess the effect of BLU-5937 vs placebo on 24-hour cough frequencyin adults with RCC (including unexplained chronic cough) and Baseline24-hourcough frequency >=8 coughs/h at Week 12.To determine the safety of BLU-5937 vs placebo in adults…